Cytori Therapeutics (NASDAQ:CYTX) Rating Reiterated by HC Wainwright

Share on StockTwits

Cytori Therapeutics (NASDAQ:CYTX)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday, September 18th. They presently have a $5.00 target price on the biotechnology company’s stock.

The analysts wrote, “Our valuation for Cytori is based on success with the current therapeutics pipeline with probability of success factors weighted in each therapeutic area. These forecasts feed into our valuation metrics, of free cash flow to the firm (FCFF), discounted EPS (dEPS) and sum- of-the-parts (SOP) models.””

A number of other analysts also recently issued reports on the stock. ValuEngine raised shares of Cytori Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, September 4th. Maxim Group downgraded shares of Cytori Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th. Finally, Zacks Investment Research raised shares of Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a report on Tuesday, July 31st. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Cytori Therapeutics presently has an average rating of “Buy” and an average price target of $10.56.

NASDAQ:CYTX traded up $0.02 during trading hours on Tuesday, hitting $0.38. The stock had a trading volume of 167,202 shares, compared to its average volume of 366,328. Cytori Therapeutics has a one year low of $0.31 and a one year high of $5.50. The company has a market cap of $3.13 million, a price-to-earnings ratio of -0.06 and a beta of 2.52.

Cytori Therapeutics (NASDAQ:CYTX) last announced its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.09). Cytori Therapeutics had a negative net margin of 380.64% and a negative return on equity of 202.09%. The firm had revenue of $1.56 million during the quarter, compared to the consensus estimate of $2.50 million. As a group, sell-side analysts forecast that Cytori Therapeutics will post -0.85 earnings per share for the current fiscal year.

About Cytori Therapeutics

Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.

See Also: How are the companies in the S&P 500 selected?

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.